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SUMMARY
It is well known that NAFLD, as well as diabetes
mellitus (DM), correlated with the progression of liver fibrosis
in chronic hepatitis C (CHC). The impact of NAFLD overlap
in chronic hepatitis B (CHB)  is not well established.
Aim. In this study we compared the prevalence of
NAFLD and related metabolic parameters in CHC and CHB,
and their relationship with disease activity and fibrosis.
Methods. The parameters of metabolic syndrome
(MetS), glucose, insulin, HOMA-IR and histological features
of steatosis / steatohepatitis were investigated in total of 700
patients with chronic viral hepatitis - CHB (n=334) and
genotype 1 CHC (n=366). Glucose and insulin were also
assessed during OGTT (60 and 120 min.) in 100 cases with
CHB and 100 – with CHC.
Results. Nonalcoholic metabolic related steatosis was
more frequent (62% v/s 48%) and severe in CHC compared
to CHB (p<0.01). MetS (51% v/s 33%), and DM OGTT (30% v/
s 20%) were found also in higher frequency in CHC than in
cases with CHB (ð<0.001). In the both type hepatitis insulin
resistance was associated with disease activity. In CHC, but
not in CHB, a positive correlation between the degree of
steatosis and the activity score was found (r = 0.322, p<0.05).
In 70% of the cases with CHB and severe steatosis (>66%)
HBV DNA was negative or <10 000 copies/ml. The advanced
liver fibrosis (F3-F4) was associated with moderate or severe
steatosis (CHC), as well as with the glucose levels, markers
of insulin resistance, and presence of DM (p<0.001), but not
with the other components of metabolic syndrome.
In conclusion, nonalcoholic metabolic related
steatosis, diabetes mellitus and insulin resistance are
associated with the both viral hepatitis, but the prevalence
is higher in chronic hepatitis C. The degree of steatosis
correlates with the activity grade and stage of fibrosis only
in patients with chronic hepatitis C. Insulin resistance and
diabetes mellitus are associated with more advanced liver
fibrosis in the both viral hepatitis.
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It is well established that liver steatosis, insulin
resistance, and diabetes mellitus have a synergic effect to
accelerate the progression of liver damage in chronic hepatitis
C genotype 1 (CHC) to cirrhosis and hepatocellular carcinoma
(1, 2, 3). In addition metabolic but not viral-induced steatosis
as well as obesity, insulin resistance and diabetes mellitus
are factors of resistance to antiviral treatment. On the other
hand the impact of nonalcoholic fatty liver disease (NAFLD)
overlap in chronic hepatitis B (CHB) is not well established
yet (4).
In this study we evaluated and compared the
prevalence of NAFLD and related metabolic parameters in
CHC and CHB, and their relationship with disease activity
and fibrosis.
MATERIALS AND METHODS
A total of 700 patients with chronic viral hepatitis were
included in this retrospective and prospective study (tabl. 1).
The patients were divided in two groups. Group I included
334 cases with CHB and group II – 366 cases with CHC
genotype 1.
The diagnosis of chronic hepatitis B and C, as well as
diabetes mellitus was based on the standard criteria.
Histological grading and staging of chronic viral hepatitis was
assessed by METAVIR scoring system, and for evaluation
of the steatosis and steatohepatitis we used Brunt’s criteria
(5). The patients with severe liver dysfunction, and alcohol
consumption more than 20g/daily for women and 40g per day
for men, and significant comorbidity which could interfere the
study results were excluded.
For the diagnosis of metabolic syndrome we used
NCEP, ATP III criteria11. Blood glucose and insulin levels were
investigated in fasting stage, and HOMA – IR was calculated
in all cases. In addition, these parameters were also evaluated
on the baseline, 60th and 120th min of the standard oral
glucose tolerance test (OGTT) with 75g glucose in 200 of the
patients (100 with CHB and 100 with CHC). The criteria for
insulin resistance included HOMA – IR >2.5, and/or
insulinaemia > 100 UI/ml of the OGTT (6, 7).
Statistical methods included Mann-Whitney test,
Anova, nonparametric and parametric correlation analysis.
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RESULTS
Liver steatosis was observed in 160 of the patients
with CHB (48%) and in 227 cases with CHC (62%). The
portions of mild (5-33%), moderate (33-66%) and severe
degree (> 66%) of steatosis were 49%, 24% and 27% for CHB,
and 20%, 56% and 24% for CHC respectively. Nonalcoholic
steatosis was more frequent and severe in patients with CHC
compared to CHB (p<0.01). In addition steatohepatitis was
observed in liver specimens in 15% (n=24) and 18% (n=41)
for patients with CHB and CHC respectively.
Metabolic syndrome was found in 110 (33%) and 185
(50.5%) patients with CHB and CHC respectively. The
percentage becomes even higher - 45.8% (n=153) for CHB and
55.1% (n=202) for CHC, when we included cases with presence
of 2 components of metabolic syndrome. Two or more
components of metabolic syndrome were presented mostly
in patients with steatosis, in 95.6% (153/160) and 88.9% (202/
227) for patients with CHB and CHC respectively (p<0.001).
The metabolic parameters in patients with chronic viral
hepatitis and steatosis are presented in table 2, and the
impairment of glucose levels (fasting and during OGTT),
among all of the patients and those with or without steatosis,
are shown in table 3 and 4. Impaired fasting glucose and
glucose tolerance, as well as diabetes mellitus were presented
mostly in patients with steatosis, as well as in those patients
with CHC (χ 2 = 86.4, ð<0.001). The mean levels of the fasting
insulin and those on OGTT, as well as HOMA – IR, were
higher in patients with steatosis compared to those without
steatosis, especially in cases with CHC (ð=0.001).
We found a positive relationships between the
presence of steatosis and the age of the patients (χ 2 = 93.4,
ð<0.01); the metabolic syndrome and its components (χ 2 =
123.6- 158.7, P<0.001, and r = 0.547- 0.644, p<0.001); the blood
glucose levels (r = 0.747, P<0.001) and presence of diabetes
mellitus (χ 2 = 163.9, P<0.001); the fasting insulin levels (r =
0.530, P<0.001) and HOMA – IR (r = 0.684, P<0.001), as well
as GGT levels (r = 0.560, P<0.001) for both viral hepatitis. In
CHC, but not in CHB, there were positive correlations between
the presence of steatosis (r=0.322, p<0.05), as well as severity
of steatosis or steatohepatitis (χ 2 = 85.5, P<0.01, r=0.347,
p<0.05), and activity grade or fibrosis staging.
No direct relationships between viral load and
steatosis, as well as metabolic parameters as signs of
metabolic syndrome, glycaemia and insulinaemia in both
hepatitis were found.  In 30 of 43 patients (70%) with CHB,
and grade 3 steatosis (>66%) and/or steatohepatitis, HBV
DNA was negative or less than 10 000 copies/ml.
In the both type hepatitis the hyperinsulinaemia was
associated with disease activity (r=0.432, p<0.01). The glucose
levels during OGTT (r =0.399, ð<0.01), and/or the presence
of diabetes mellitus (χ 2 = 134.2, (ð<0.001), as well as HOMA-
IR (r = 0.423, p<0.01) and the degree of hyperinsulinaemia
during OGTT (r = 0.386, p<0.01, χ2  = 76.4, p<0.05) also
correlated with advance fibrosis (F3-F4).
DISCUSSION
Many data about relationship of CHC and steatosis,
metabolic syndrome, obesity, insulin resistance as well as
diabetes mellitus have been collected (1, 2, 3, 4). On the
opposed only a small number of studies reported steatosis,
obesity and MS prevalence in CHB have been published (4,
8, 9, 10). Some of them compared CHC and CHB for the
prevalence of those metabolic factors. In our study we also
evaluated and compared the prevalence of NAFLD and related
metabolic parameters in CHC and CHB, and their relationship
with disease activity and fibrosis.
The prevalence of steatosis of 62% in Bulgarian
patients with chronic hepatitis C genotype 1 is near to the
reported mean prevalence of 55%, with range of 38% to 80%
(11, 12, 13). Our results also show a strong association
between liver steatosis and metabolic syndrome. All metabolic
disturbances were presented mostly in patients with steatosis.
Like the results to the other authors, we also found the
relationship between liver steatosis and hyperglycaemia and
surrogate markers of insulin resistance, as well as disease
activity and fibrosis staging. The prevalence of liver steatosis,
insulin resistance and type 2 diabetes mellitus in patients with
chronic hepatitis C is higher than reported in the general
population (14). There is complex relationship between these
factors. Every one of them is also an important independent
co-factor in the worsening of liver disease (4, 15, 16). In
addition these factors have a synergic effect to the
progression of chronic hepatitis C to cirrhosis and
hepatocellular carcinoma, and also can influence the response
to antiviral treatment (16).
On the other hand, most of the data show that a
steatosis prevalence in patients with CHB is similar to that
of the general population (8, 9, 10, 17). In these studies the
presence of steatosis correlates with BMI and metabolic
parameters as waist circumference, high blood pressure and
dyslipidemia, but not with viral genotype or viral load, and
fibrosis (4, 8). We also found less prevalence and degree of
steatosis as well as metabolic disturbances in CHB patients
in Bulgaria than those with CHC. As HCV-related steatosis,
steatosis in patients with CHB also associates with
parameters of metabolic syndrome and markers of insulin
resistance. In CHB patients with severe steatosis and/or
steatohepatitis we observed low viral load or negative HBV
DNA, but in generally there were no relationships between
viral load and steatosis or metabolic parameters in both
hepatitis.
On the opposite to CHC, steatosis in our patients with
chronic HBV infection did not correlate with fibrosis. On the
other hand hyperinsulinaemia as well as markers of insulin
resistance were   associated with disease activity and fibrosis
in the both type hepatitis. Consecuently, in HBV related
chronic hepatitis, steatosis is probably also a cofactor of liver
disease worsening in patients with metabolic syndrome,
diabetes mellitus or steatohepatitis.  / JofIMAB 2011, vol. 17, book 1 /  195
CONCLUSIONS
Nonalcoholic metabolic related steatosis, diabetes
mellitus and insulin resistance are associated with the both
viral hepatitis, but the prevalence is higher in chronic
hepatitis C.
The degree of steatosis correlates with the activity
grade and stage of fibrosis only in patients with chronic
hepatitis C.
Insulin resistance and diabetes mellitus are associated
with more advanced liver fibrosis in the both viral hepatitis.
Table 1.  Mean characteristic of the patients with CHB and CHC.
Markers Group I (patients with CHB, n=334) Group II (patients with CHC, n=334)
Average age  (x±SD) 42.7±13.9 45.9±14.1
Sex – male/female (n) 122/112 165 / 201
ALAT  (IU/L), (x±SD) 90.2±98.4 76.4±103.9
ASAT  (IU/L), (x±SD) 64.4±72.0 52.0±48.2
GGT  (IU/L), (x±SD) 46.3±52.2 55.2±49.4
Table 2. The metabolic parameters in patients with chronic viral hepatitis and steatosis.
Metabolic parameters CHB with steatosis (n=160) CHC with steatosis  (n=227)
BMI (êg/m²), (x±SD) 25.9±3.5 25.5±3.3
Waist circumference
(>102 cm /male >88 cm/female), (n/ %) 124 / 77.5% 181 / 79.7%
Hypertension (n / %) 51 / 31.8% 72 /  31.7%
Total cholesterol (mmol/l), (x±SD) 5.7 ±1.2 5.5±1.6
HDL- cholesterol (mmol/l), (x±SD) 0.95 ± 0.05 0.87 ± 0.08
LDL- cholesterol (mmol/l), (x±SD) 2.4 ± 0.2 2.6 ± 0.5
Triglycerides (mmol/l), (x±SD) 2.07± 0.4 2.3 ± 0.3
Fasting glucose (mmol/l), (x±SD) 4.8± 1.76 5.1±2.2
Table 3. The impairment of fasting glucose and insulin levels in patients with chronic hepatitis B and C, and those
with or without steatosis.
Parameter CHB CHC
Total Steatosis (+), Steatosis (-), Total Steatosis (+), Steatosis (-),
(n=334) (n=160) (n=174) (n=366) (n=227)  (n=139)
Impaired fasting glucose
(6.1- 7.0 mmol/l), (%) 29/9% 24 /15% 5 /3% 42/12% 36 /16% 6 / 4%
Diabetes mellitus
(fasting glucose
>7.0 mmol/l), (n/%) 17/5 % 13/ 8% 4 / 2% 37 /10% 30 / 13% 7 / 5%
Fasting insulin
(UI/ml), (x±SD) 17.9±6.4 20.4±10.2 13.2±4.2 18.4±7.5 25.6±12.2 13.0±4.2
ÍÎÌÀ-IR (x±SD) 2.5±.2.8 5.2 ±0.2 2.0±0.8 2.9±3.2 6.0±0.2 2.2±1.3196  / JofIMAB 2011, vol. 17, book 1 /
Table 4. The impairment of glucose and insulin levels during OGTT in patients with chronic hepatitis B and C, and
those with and without steatosis.
Parameter CHB CHC
Total Steatosis (+), Steatosis (-), Total Steatosis (+), Steatosis (-),
(n=100) (n=44) (n=56) (n=100) (n=45) (n=55)
Impaired glucose
tolerance (n/%) 30 / 30% 22 / 50% 8 / 14% 20 / 20% 18 / 40% 2/4%
Diabetes mellitus (n/%) 20/20% 18/41% 2/4% 30/30% 25/55% 3/5%
Insulin (UI/ml),
(60 min - OGTT), (x±SD) 121±100.5 123±71.4 119±98.3 121±102.7 124±89.2 120±96.2
Insulin (UI/ml),
(120 min- OGTT), (x±SD) 96±82.5 116±75.2 76±80.1 110±92.8 128±82.5 99±89.2
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